Merus NV (MRUS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1137942,
    "name": "Merus NV",
    "stock_name": "Merus NV",
    "full_name": "Merus NV",
    "name_url": "stocks-analysis/merus-nv",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "96.22",
    "chg": 0.23,
    "chgp": "0.24%",
    "dir": 1,
    "prev_price": "95.99",
    "mcapval": "5,081.87",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "NL0011606264",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.85 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/merus-nv-1137942-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Merus NV Hits New 52-Week High of $95.30, Up 77.78%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/merus-nv-hits-new-52-week-high-of-9530-up-7778-3659165",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MerusNV_priceRelatedfactors_3659165.png",
        "date": "2025-10-30 18:42:38",
        "description": "Merus NV, a small-cap biotechnology firm, reached a new 52-week high of USD 95.30 on October 29, 2025, marking a 77.78% increase over the past year. With a market capitalization of USD 5,082 million, the company continues to face challenges, including a negative return on equity."
      },
      {
        "title": "Merus NV Hits New 52-Week High of $95.06, Up 77.91%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/merus-nv-hits-new-52-week-high-of-9506-up-7791-3649270",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MerusNV_priceRelatedfactors_3649270.png",
        "date": "2025-10-27 16:56:08",
        "description": "Merus NV has achieved a new 52-week high, reflecting a strong performance with a significant stock appreciation over the past year. As a small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of over USD 5 billion, showcasing resilience in a competitive landscape."
      },
      {
        "title": "Merus NV Hits New 52-Week High of $95.02, Up 77.85%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/merus-nv-hits-new-52-week-high-of-9502-up-7785-3620140",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MerusNV_priceRelatedfactors_3620140.png",
        "date": "2025-10-14 18:53:07",
        "description": "Merus NV achieved a new 52-week high of USD 95.02 on October 13, 2025, reflecting a significant increase over the past year. With a market capitalization of USD 5,082 million, the company remains unprofitable, indicated by its negative price-to-earnings ratio and a high price-to-book ratio."
      },
      {
        "title": "Merus NV Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/merus-nvs-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-performance-3617290",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MerusNV_technicaldot_3617290.png",
        "date": "2025-10-13 15:23:22",
        "description": "Merus NV, a small-cap pharmaceutical and biotechnology company, is currently trading at 94.37, slightly below its previous close. The stock has shown significant outperformance against the S&P 500 over the past year and year-to-date, indicating a strong market position despite mixed technical indicators."
      },
      {
        "title": "Merus NV Hits Day High with 36.67% Surge in Intraday Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/merus-nv-hits-day-high-with-3667-surge-in-intraday-performance-3585889",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/MerusNV_priceRelatedfactors_3585889.png",
        "date": "2025-10-01 16:16:19",
        "description": "Merus NV, a small-cap biotechnology firm, saw significant stock activity on September 30, 2025, with a notable intraday high. The company has demonstrated impressive long-term gains, outperforming major indices, but faces challenges such as declining net sales and negative operating cash flow, indicating potential financial risks."
      },
      {
        "title": "Is Merus NV technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-merus-nv-technically-bullish-or-bearish-3546895",
        "imagepath": "",
        "date": "2025-09-20 19:42:36",
        "description": "As of 11 September 2025, the technical trend for Merus NV has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish MACD readings on both weekly and monthly time frames, and a bullish daily moving average. However, the weekly and monthly RSI readings are bearish, indicating potential weakness. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. Dow Theory indicates a bullish monthly trend, but no trend on the weekly. The On-Balance Volume is mildly bullish on both time frames.\n\nIn terms of performance, Merus NV has outperformed the S&P 500 across multiple periods, with a year-to-date return of 63.97% compared to the S&P 500's 12.22%, and a three-year return of 208.09% versus 70.41% for the benchmark...."
      },
      {
        "title": "Is Merus NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-merus-nv-overvalued-or-undervalued-3543378",
        "imagepath": "",
        "date": "2025-09-20 18:17:46",
        "description": "As of 7 November 2016, the valuation grade for Merus NV moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued, particularly given its high Price to Book Value of 7.02 and negative EV to EBIT and EV to EBITDA ratios of -12.39 and -12.49, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -215.67%, further underscoring the challenges the company faces.\n\nIn comparison to its peers, Merus NV's EV to EBITDA ratio of -12.49 is less favorable than Arcellx, Inc. at -16.81 and CymaBay Therapeutics, Inc. at -34.09, suggesting that Merus is not performing as well as its competitors in the same industry. Despite this, the company has shown impressive stock performance, with a year-to-date return of 63.97%, significantly outpacing the S&P 500's 12.22% return during the same period. Howe..."
      }
    ],
    "total": 12,
    "sid": "1137942",
    "stock_news_url": "https://www.marketsmojo.com/news/merus-nv-1137942"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Merus NV Hits New 52-Week High of $95.30, Up 77.78%

2025-10-30 18:42:38

Merus NV, a small-cap biotechnology firm, reached a new 52-week high of USD 95.30 on October 29, 2025, marking a 77.78% increase over the past year. With a market capitalization of USD 5,082 million, the company continues to face challenges, including a negative return on equity.

Merus NV Hits New 52-Week High of $95.06, Up 77.91%

2025-10-27 16:56:08

Merus NV has achieved a new 52-week high, reflecting a strong performance with a significant stock appreciation over the past year. As a small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of over USD 5 billion, showcasing resilience in a competitive landscape.

Merus NV Hits New 52-Week High of $95.02, Up 77.85%

2025-10-14 18:53:07

Merus NV achieved a new 52-week high of USD 95.02 on October 13, 2025, reflecting a significant increase over the past year. With a market capitalization of USD 5,082 million, the company remains unprofitable, indicated by its negative price-to-earnings ratio and a high price-to-book ratio.

Merus NV Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-10-13 15:23:22

Merus NV, a small-cap pharmaceutical and biotechnology company, is currently trading at 94.37, slightly below its previous close. The stock has shown significant outperformance against the S&P 500 over the past year and year-to-date, indicating a strong market position despite mixed technical indicators.

Merus NV Hits Day High with 36.67% Surge in Intraday Performance

2025-10-01 16:16:19

Merus NV, a small-cap biotechnology firm, saw significant stock activity on September 30, 2025, with a notable intraday high. The company has demonstrated impressive long-term gains, outperforming major indices, but faces challenges such as declining net sales and negative operating cash flow, indicating potential financial risks.

Is Merus NV technically bullish or bearish?

2025-09-20 19:42:36

As of 11 September 2025, the technical trend for Merus NV has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish MACD readings on both weekly and monthly time frames, and a bullish daily moving average. However, the weekly and monthly RSI readings are bearish, indicating potential weakness. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the KST is bullish weekly but mildly bearish monthly. Dow Theory indicates a bullish monthly trend, but no trend on the weekly. The On-Balance Volume is mildly bullish on both time frames. In terms of performance, Merus NV has outperformed the S&P 500 across multiple periods, with a year-to-date return of 63.97% compared to the S&P 500's 12.22%, and a three-year return of 208.09% versus 70.41% for the benchmark....

Is Merus NV overvalued or undervalued?

2025-09-20 18:17:46

As of 7 November 2016, the valuation grade for Merus NV moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued, particularly given its high Price to Book Value of 7.02 and negative EV to EBIT and EV to EBITDA ratios of -12.39 and -12.49, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -215.67%, further underscoring the challenges the company faces. In comparison to its peers, Merus NV's EV to EBITDA ratio of -12.49 is less favorable than Arcellx, Inc. at -16.81 and CymaBay Therapeutics, Inc. at -34.09, suggesting that Merus is not performing as well as its competitors in the same industry. Despite this, the company has shown impressive stock performance, with a year-to-date return of 63.97%, significantly outpacing the S&P 500's 12.22% return during the same period. Howe...

View All News